StreetInsider.com News Articles

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Wed, 19 Aug 2026 16:05:00 -0400

HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted at an exercise price of $31.48 per share. Each option award will vest over a 4-year

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Wed, 19 Aug 2026 16:05:00 -0400

The stock options that were granted at an exercise price of $31.48 per share. Each option award will vest over a 4-year

Form 10-Q vTv Therapeutics Inc. For: Jun 30

Thu, 06 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260806/26884581.html

Form 10-Q vTv Therapeutics Inc. For: Jun 30

Thu, 06 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260806/26884581.html

Form 8-K vTv Therapeutics Inc. For: Aug 06

Thu, 06 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260806/26884402.html

Form 8-K vTv Therapeutics Inc. For: Aug 06

Thu, 06 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260806/26884402.html

vTv Therapeutics (VTVT) Misses Q2 EPS by 15c

Thu, 06 Aug 2026 08:17:20 -0400

vTv Therapeutics (NASDAQ: VTVT) reported Q2 EPS of ($1.05), $0.15 worse than the analyst estimate of ($0.90).

For earnings history and earnings-related data on vTv Therapeutics (VTVT) click here.

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 08:00:00 -0400

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026

Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026

Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout

Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D

HIGH POINT, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT),

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 08:00:00 -0400

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026

Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026

Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout

Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D

HIGH POINT, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT),

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 08:00:00 -0400

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026

Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026

Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout

Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D

HIGH POINT, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT),

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 08:00:00 -0400

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026

Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026

Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout

Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D

HIGH POINT, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT),

Form SCHEDULE 13G/A vTv Therapeutics Inc. Filed by: MILLENNIUM MANAGEMENT LLC

Wed, 29 Jul 2026 18:45:00 -0400

si-local-file:///var/storage/secattach/20260729/26836780.html

Form SCHEDULE 13G/A vTv Therapeutics Inc. Filed by: MILLENNIUM MANAGEMENT LLC

Wed, 29 Jul 2026 18:45:00 -0400

si-local-file:///var/storage/secattach/20260729/26836780.html

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 28 Jul 2026 16:05:00 -0400

HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 23,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have a weighted average exercise price of $31.95 per share. Each option award will vest over

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 28 Jul 2026 16:05:00 -0400

The stock options that were granted have a weighted average exercise price of $31.95 per share. Each option award will vest over

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 12,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have a weighted average exercise price of $34.15 per share. Each option award will vest over a

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

The stock options that were granted have a weighted average exercise price of $34.15 per share. Each option award will vest over a

Rodman & Renshaw Starts vTv Therapeutics (VTVT) at Buy

Tue, 30 Jun 2026 07:56:52 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on vTv Therapeutics (NASDAQ: VTVT) with a Buy rating and a price target of $67.00.

The analyst comments "We are initiating coverage of vTv Therapeutics with a BUY rating and $67 price target anchored to the commercial potential of cadisegliatin (TTP399), a first‑in‑class oral, liver‑selective glucokinase activator in development as an adjunct to insulin for Type 1 diabetes (T1D). Cadisegliatin holds FDA Breakthrough Therapy designation and Phase 2 data showing improved HbA1c, fewer hypoglycemic events, and no increase in diabetic ketoacidosis (DKA), supporting a differentiated clinical profile versus prior adjunctive T1D therapies.

Rodman & Renshaw Starts vTv Therapeutics (VTVT) at Buy

Tue, 30 Jun 2026 07:56:52 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on vTv Therapeutics (NASDAQ: VTVT) with a Buy rating and a price target of $67.00.

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: 667, L.P.

Mon, 29 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260629/26707115.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: 667, L.P.

Mon, 29 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260629/26707115.html

Form 8-K vTv Therapeutics Inc. For: Jun 26

Mon, 29 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260629/26706620.html

Form 8-K vTv Therapeutics Inc. For: Jun 26

Mon, 29 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260629/26706620.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: AKKARAJU SRINIVAS

Mon, 29 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260629/26706527.html

Form 4 vTv Therapeutics Inc. For: Jun 26 Filed by: AKKARAJU SRINIVAS

Mon, 29 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260629/26706527.html